GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Shiller PE Ratio

Pacira BioSciences (Pacira BioSciences) Shiller PE Ratio : 98.08 (As of Apr. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Shiller PE Ratio?

As of today (2024-04-25), Pacira BioSciences's current share price is $25.50. Pacira BioSciences's E10 for the quarter that ended in Dec. 2023 was $0.26. Pacira BioSciences's Shiller PE Ratio for today is 98.08.

The historical rank and industry rank for Pacira BioSciences's Shiller PE Ratio or its related term are showing as below:

PCRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 97.88   Med: 176.69   Max: 500.88
Current: 98.08

During the past years, Pacira BioSciences's highest Shiller PE Ratio was 500.88. The lowest was 97.88. And the median was 176.69.

PCRX's Shiller PE Ratio is ranked worse than
92.22% of 514 companies
in the Drug Manufacturers industry
Industry Median: 24.47 vs PCRX: 98.08

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Pacira BioSciences's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.26 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pacira BioSciences Shiller PE Ratio Historical Data

The historical data trend for Pacira BioSciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Shiller PE Ratio Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 128.70

Pacira BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 519.09 190.82 128.70

Competitive Comparison of Pacira BioSciences's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Shiller PE Ratio falls into.



Pacira BioSciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pacira BioSciences's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=25.50/0.26
=98.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Pacira BioSciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.52/129.4194*129.4194
=0.520

Current CPI (Dec. 2023) = 129.4194.

Pacira BioSciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.340 99.695 -0.441
201406 -0.140 100.560 -0.180
201409 -0.080 100.428 -0.103
201412 0.140 99.070 0.183
201503 0.030 99.621 0.039
201506 0.000 100.684 0.000
201509 0.080 100.392 0.103
201512 -0.070 99.792 -0.091
201603 -0.100 100.470 -0.129
201606 -0.210 101.688 -0.267
201609 -0.590 101.861 -0.750
201612 -0.110 101.863 -0.140
201703 -0.520 102.862 -0.654
201706 -0.490 103.349 -0.614
201709 -0.190 104.136 -0.236
201712 0.110 104.011 0.137
201803 -0.260 105.290 -0.320
201806 0.060 106.317 0.073
201809 -0.020 106.507 -0.024
201812 0.200 105.998 0.244
201903 -0.070 107.251 -0.084
201906 0.060 108.070 0.072
201909 -0.150 108.329 -0.179
201912 -0.120 108.420 -0.143
202003 0.190 108.902 0.226
202006 -0.170 108.767 -0.202
202009 2.940 109.815 3.465
202012 0.320 109.897 0.377
202103 0.230 111.754 0.266
202106 0.420 114.631 0.474
202109 0.390 115.734 0.436
202112 -0.120 117.630 -0.132
202203 0.150 121.301 0.160
202206 0.400 125.017 0.414
202209 -0.020 125.227 -0.021
202212 -0.220 125.222 -0.227
202303 -0.430 127.348 -0.437
202306 0.510 128.729 0.513
202309 0.230 129.860 0.229
202312 0.520 129.419 0.520

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pacira BioSciences  (NAS:PCRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Pacira BioSciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (Pacira BioSciences) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
Executives
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Ellis Ronald J. Jr. officer: Chief Strategy Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Max Reinhardt officer: President C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
David M Stack director, officer: President and CEO THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Dennis Mcloughlin officer: Chief Commercial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054